Liposarcoma: Advances in Cellular and Molecular Genetics Alterations and Corresponding Clinical Treatment

Overview

Journal J Cancer

Specialty Oncology

Date 2020 Jan 2

PMID 31892977

Citations 22

Authors

Lingge Yang

Shiqi Chen

Peng Luo

Wangjun Yan

Chunmeng Wang

Affiliations

Soon will be listed here.

Abstract

Liposarcoma is a malignant tumor of mesenchymal origin with significant tissue diversity. It is composed of adipocytes with different degrees of differentiation and different degrees of heteromorphosis. It is not sensitive to traditional radiotherapy and chemotherapy and has a poor prognosis. In recent years, with the rapid development of basic immunology, molecular genetics and tumor molecular biology, the histological classification of liposarcoma has become increasingly clear. More and more new methods and technologies, such as gene expression profile analysis, the whole genome sequencing, miRNA expression profile analysis and RNA sequencing, have been successfully applied to liposarcoma, bringing about a deeper understanding of gene expression changes and molecular pathogenic mechanisms in the occurrence and development of liposarcoma. This study reviews the present research status and progress of cellular and molecular alterations of liposarcoma and corresponding clinical treatment progress.

Citing Articles

Primary giant liposarcoma of the gallbladder: a case report and literature review.

Yang Y, Hou Y, Yi L, Chen C, Tang L, Hu M World J Surg Oncol. 2025; 23(1):61.

PMID: 39987143 PMC: 11846246. DOI: 10.1186/s12957-025-03711-7.

Comprehensive Analysis of a Six-Gene Signature Predicting Survival and Immune Infiltration of Liposarcoma Patients and Deciphering Its Therapeutic Significance.

Han J, Zhao B, Han X, Sun T, Yue M, Hou M Int J Mol Sci. 2024; 25(14).

PMID: 39063036 PMC: 11277418. DOI: 10.3390/ijms25147792.

An overview on liposarcoma subtypes: Genetic alterations and recent advances in therapeutic strategies.

M S A, K C, Bhargavan R, Somanathan T, Subhadradevi L J Mol Histol. 2024; 55(3):227-240.

PMID: 38696048 DOI: 10.1007/s10735-024-10195-4.

Parosteal lipoma of the left femur: A case report.

Waters J, Horenstein S, Egger A, Johnsen P, Kim T Clin Case Rep. 2024; 12(4):e8744.

PMID: 38654936 PMC: 11035377. DOI: 10.1002/ccr3.8744.

Notch signaling regulates a metabolic switch through inhibiting PGC-1α and mitochondrial biogenesis in dedifferentiated liposarcoma.

Tien P, Chen X, Elzey B, Pollock R, Kuang S Oncogene. 2023; 42(34):2521-2535.

PMID: 37433985 PMC: 10575759. DOI: 10.1038/s41388-023-02768-6.

References

Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyaki M, Yamamoto N . Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. Biochem Biophys Res Commun. 2018; 506(4):912-917. DOI: 10.1016/j.bbrc.2018.10.119. View

Dickson M, Tap W, Keohan M, DAngelo S, Gounder M, Antonescu C . Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol. 2013; 31(16):2024-8. PMC: 3661937. DOI: 10.1200/JCO.2012.46.5476. View

Kang Y, Horvai A . p16 Immunohistochemistry is Less Useful Than MDM2 and CDK4 to Distinguish Dedifferentiated Liposarcomas From Other Retroperitoneal Mimics. Appl Immunohistochem Mol Morphol. 2015; 25(1):58-63. DOI: 10.1097/PAI.0000000000000270. View

Guan Z, Yu X, Wang H, Wang H, Zhang J, Li G . Advances in the targeted therapy of liposarcoma. Onco Targets Ther. 2015; 8:125-36. PMC: 4293924. DOI: 10.2147/OTT.S72722. View

De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada G . Identification of a gene expression driven progression pathway in myxoid liposarcoma. Oncotarget. 2014; 5(15):5965-77. PMC: 4171605. DOI: 10.18632/oncotarget.2023. View

Jing W, Lan T, Chen H, Zhang Z, Chen M, Peng R . Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases. Histopathology. 2018; 72(7):1145-1155. DOI: 10.1111/his.13473. View

Delcroix V, Mauduit O, Tessier N, Montillaud A, Lesluyes T, Ducret T . The Role of the Anti-Aging Protein Klotho in IGF-1 Signaling and Reticular Calcium Leak: Impact on the Chemosensitivity of Dedifferentiated Liposarcomas. Cancers (Basel). 2018; 10(11). PMC: 6266342. DOI: 10.3390/cancers10110439. View

Ramirez-Bellver J, Lopez J, Macias E, Alegria-Landa V, Gimeno I, Perez-Plaza A . Primary dermal pleomorphic liposarcoma: utility of adipophilin and MDM2/CDK4 immunostainings. J Cutan Pathol. 2016; 44(3):283-288. DOI: 10.1111/cup.12850. View

Klein M, Dickson M, Antonescu C, Qin L, Dooley S, Barlas A . PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence. Oncogene. 2018; 37(37):5066-5078. PMC: 6137027. DOI: 10.1038/s41388-018-0332-y. View

10.

Safavi S, Jarnum S, Vannas C, Udhane S, Jonasson E, Tesan Tomic T . HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget. 2015; 7(1):433-45. PMC: 4808009. DOI: 10.18632/oncotarget.6336. View

11.

Tap W, Eilber F, Ginther C, Dry S, Reese N, Barzan-Smith K . Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization. Genes Chromosomes Cancer. 2010; 50(2):95-112. DOI: 10.1002/gcc.20835. View

12.

Hemminger J, Toland A, Scharschmidt T, Mayerson J, Kraybill W, Guttridge D . The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas. Mod Pathol. 2012; 26(2):282-8. DOI: 10.1038/modpathol.2012.133. View

13.

Nishio J, Aoki M, Nabeshima K, Iwasaki H, Naito M . Cytogenetic and molecular cytogenetic findings in giant dedifferentiated liposarcoma of the thigh. Oncol Rep. 2011; 27(3):764-8. DOI: 10.3892/or.2011.1584. View

14.

Jo V, Fletcher C . WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46(2):95-104. DOI: 10.1097/PAT.0000000000000050. View

15.

Nabeshima A, Matsumoto Y, Fukushi J, Iura K, Matsunobu T, Endo M . Tumour-associated macrophages correlate with poor prognosis in myxoid liposarcoma and promote cell motility and invasion via the HB-EGF-EGFR-PI3K/Akt pathways. Br J Cancer. 2015; 112(3):547-55. PMC: 4453656. DOI: 10.1038/bjc.2014.637. View

16.

Ray-Coquard I, Blay J, Italiano A, Cesne A, Penel N, Zhi J . Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol. 2012; 13(11):1133-40. DOI: 10.1016/S1470-2045(12)70474-6. View

17.

Thway K, Jones R, Noujaim J, Zaidi S, Miah A, Fisher C . Dedifferentiated Liposarcoma: Updates on Morphology, Genetics, and Therapeutic Strategies. Adv Anat Pathol. 2015; 23(1):30-40. DOI: 10.1097/PAP.0000000000000101. View

18.

Ghadimi M, Liu P, Peng T, Bolshakov S, Young E, Torres K . Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011; 117(23):5359-69. PMC: 3161152. DOI: 10.1002/cncr.26195. View

19.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

20.

Bill K, Casadei L, Prudner B, Iwenofu H, Strohecker A, Pollock R . Liposarcoma: molecular targets and therapeutic implications. Cell Mol Life Sci. 2016; 73(19):3711-8. PMC: 7175098. DOI: 10.1007/s00018-016-2266-2. View